Healthcare provider profile · identity verified

James Vincent Libbon, M.D.

Internal Medicine · ARVADA, CO · NPI 1740523323

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	250	97
Metformin Hcl	Metformin Hcl	173	80
Duloxetine Hcl	Duloxetine Hcl	152	67
Lisinopril	Lisinopril	137	56
Rosuvastatin Calcium	Rosuvastatin Calcium	110	41
Losartan Potassium	Losartan Potassium	103	39
Albuterol Sulfate Hfa	Albuterol Sulfate	102	63
Jardiance	Empagliflozin	102	37
Levothyroxine Sodium	Levothyroxine Sodium	97	39
Amlodipine Besylate	Amlodipine Besylate	94	38
Meloxicam	Meloxicam	90	47
Tamsulosin Hcl	Tamsulosin Hcl	89	44
Ozempic	Semaglutide	83	15
Pravastatin Sodium	Pravastatin Sodium	76	29
Metformin Hcl Er	Metformin Hcl	68	30
Hydrochlorothiazide	Hydrochlorothiazide	65	27
Omeprazole	Omeprazole	64	41
Pantoprazole Sodium	Pantoprazole Sodium	64	31
Trazodone Hcl	Trazodone Hcl	62	26
Gabapentin	Gabapentin	59	27
Triamcinolone Acetonide	Triamcinolone Acetonide	59	33
Metoprolol Tartrate	Metoprolol Tartrate	57	27
Celecoxib	Celecoxib	56	31
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	52	20
Metoprolol Succinate	Metoprolol Succinate	52	20
Oxycodone Hcl	Oxycodone Hcl	49	12
Shingrix	Varicella-Zoster Ge/As01b/Pf	47	44
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	46	22
Pradaxa	Dabigatran Etexilate Mesylate	46	19
Arexvy	Rsvpref3 Antigen/As01e/Pf	45	45
Spiriva Respimat	Tiotropium Bromide	45	21
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	44	44
Furosemide	Furosemide	42	21
Mirtazapine	Mirtazapine	42	19
Solifenacin Succinate	Solifenacin Succinate	40	16
Glipizide Er	Glipizide	38	17
Sertraline Hcl	Sertraline Hcl	37	13
Wixela Inhub	Fluticasone Propion/Salmeterol	37	21
Prednisone	Prednisone	35	30
Finasteride	Finasteride	32	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Azelastine Hcl	Azelastine Hcl	28	23
Buprenorphine	Buprenorphine	28	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	28	12
Fluticasone Propionate	Fluticasone Propionate	28	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	28	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	28	13
Morphine Sulfate Er	Morphine Sulfate	28	suppressed
Topiramate	Topiramate	27	suppressed
Chlorthalidone	Chlorthalidone	25	11
Glipizide	Glipizide	25	16
Testosterone	Testosterone	25	suppressed
Allopurinol	Allopurinol	24	suppressed
Bupropion Xl	Bupropion Hcl	24	12
Simvastatin	Simvastatin	21	suppressed
Alvesco	Ciclesonide	20	suppressed
Myrbetriq	Mirabegron	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Alendronate Sodium	Alendronate Sodium	19	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Atenolol	Atenolol	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	12
Famotidine	Famotidine	18	suppressed
Glimepiride	Glimepiride	17	suppressed
Potassium Chloride	Potassium Chloride	17	11
Escitalopram Oxalate	Escitalopram Oxalate	16	suppressed
Ibuprofen	Ibuprofen	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Humulin N	Insulin Nph Human Isophane	15	suppressed
Methocarbamol	Methocarbamol	15	suppressed
Butalbital-Aspirin-Caffeine	Butalbital/Aspirin/Caffeine	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Amoxicillin	Amoxicillin	13	11
Clopidogrel	Clopidogrel Bisulfate	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	11
Ezetimibe	Ezetimibe	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Carvedilol	Carvedilol	11	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Tadalafil	Tadalafil	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error